375853-82-0

Basic information

• Product Name: 1,2,3,6-TETRAHYDROPYRIDINE-4-YL-BORONIC ACID PINACOL ESTER
• Synonyms: 1,2,3,6-TETRAHYDROPYRIDINE-4-YL-BORONIC ACID PINACOL ESTER;1,2,3,6-Tetrahydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine;1,2,3,6-Tetrahydropyridine-4-boronic acid pinacol ester;Pyridine, 1,2,3,6-tetrahydro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;4-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine;1,2,3,6-Tetrahydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl);(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 375853-82-0
• Molecular Formula: C₁₆H₂₈BNO₄
• Molecular Weight: 209.09
• Mol File: 375853-82-0.mol

Chemical Properties

• Boiling Point: 246℃
• Flash Point: 103℃
• Appearance: /
• Density: 0.99
• Vapor Pressure: 0.0278mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 10.66±0.10(Predicted)
• CAS DataBase Reference: 1,2,3,6-TETRAHYDROPYRIDINE-4-YL-BORONIC ACID PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,6-TETRAHYDROPYRIDINE-4-YL-BORONIC ACID PINACOL ESTER(375853-82-0)
• EPA Substance Registry System: 1,2,3,6-TETRAHYDROPYRIDINE-4-YL-BORONIC ACID PINACOL ESTER(375853-82-0)

Safety Data

• Hazardous Substances Data: 375853-82-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1,2,3,6-Tetrahydropyridine-4-yl-boronic acid pinacol ester is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, 1,2,3,6-tetrahydropyridine-4-yl-boronic acid pinacol ester is used as a reagent, particularly in the Suzuki-Miyaura cross-coupling reaction. It acts as a boron source, facilitating the formation of carbon-carbon bonds, which is crucial for the creation of complex organic molecules.
Used in Material Development:
1,2,3,6-TETRAHYDROPYRIDINE-4-YL-BORONIC ACID PINACOL ESTER's unique properties also make it a valuable tool in the development of new materials, where its reactivity and structure can be leveraged to produce innovative substances with specific properties.
Safety Considerations:
Due to its potential health and safety risks, 1,2,3,6-tetrahydropyridine-4-yl-boronic acid pinacol ester should be handled with caution in laboratory settings and industrial applications to ensure the safety of users and the environment.

InChI:InChI=1/C11H20BNO2/c1-10(2)11(3,4)15-12(14-10)9-5-7-13-8-6-9/h5,13H,6-8H2,1-4H3

Upstream product

• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 24608-52-4 tert-butyl chloroformate 
• 181219-01-2 4-pyridineboronic acid pinacol ester 
• 159503-91-0 tert-butyl 4-bromo-5,6-dihydropyridine-1(2H)-carboxylate 
• 1195-66-0 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 73183-34-3 bis(pinacol)diborane 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1386393-97-0 tert-butyl 4-[(1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 41979-39-9 4-piperidone hydrochloride 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 643746-86-5 tert-butyl 4-(5-{[(benzyloxy)carbonyl]amino}-2,4-difluorophenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 853643-60-4 tert-butyl 4-(3-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 474333-13-6 4-[2,6-Bis-(2-trifluoromethyl-phenoxymethyl)-phenyl]-1,2,3,6-tetrahydro-pyridine 
• 920285-16-1 4-[1-(3-Fluoro-benzyl)-2,3-dioxo-2,3-dihydro-1H-indol-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 938195-81-4 methyl 4-[1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-N-(2,6-dichlorobenzoyl)-L-phenylalaninate 
• 938195-30-3 methyl N-(tert-butoxycarbonyl)-4-[1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-L-phenylalaninate 
• 935857-01-5 4-[4-(2-ethyl-butyrylamino)-2-fluoro-phenyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 876343-86-1 4-(5-bromo4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 938083-10-4 methyl 3-(5-[1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]pyridin-2-yl)-N-(2,6-dichlorobenzoyl)-L-alaninate 
• 941316-94-5 4-(N-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-[3-(tert-butyldimethylsilyloxymethyl)phenyl]-6-morpholinopyrimidine 
• 946505-36-8 tert-butyl 4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 944255-98-5 C₂₇H₃₀N₂O₆ 
• 607744-56-9 tert-butyl 4-(4-chloro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 1056646-21-9 C₂₃H₂₉FN₂O₃ 

Relevant articles and documents

COMPOUNDS FOR TARGETED DEGRADATION OF BRD9

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Synthesis method of N-methyl-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester

The invention belongs to the field of synthesis of medical intermediates, and particularly relates to a synthesis method of N-methyl-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester. According to the method, N-Boc-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester is selected as a raw material, Boc protection is removed under an acidic condition, paraformaldehyde, a reducing reagent and HOBt are added for an N-methylation reaction, the method can effectively inhibit the occurrence of quaternary ammonium salt side reactions, the post-treatment is simple, and the method is suitable for industrial production. The crude product is recrystallized to obtain the N-methyl-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester product with the purity of more than 98.0%, and the two-step molar yield is more than 90%.

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

Preparation method of N-substituted-tetrahydropyridine-3/4-boric acid/ester

The invention discloses a preparation method of N-substituted tetrahydropyridine-3/4-boric acid/ester, and belongs to the technical field of organic boric acid chemistry. The method comprises the following steps: carrying out a reaction on pyridine-3/4-boric acid/ester and a halide to form a quaternary salt, and reducing the quaternary salt with sodium/potassium borohydride in an aprotic solvent to generate N-substituted-tetrahydropyridine-3/4-boric acid/ester. According to the method, easily-synthesized pyridine-3/4-boric acid/ester is used as a raw material, the product can be obtained through two continuous steps, and the reaction selectivity is high, so that the defect that palladium-catalyzed coupling or ultralow temperature is needed when substituted piperidone is adopted as a raw material is overcome, the method is verified on the hectogram scale, and a concise and efficient synthesis path is provided for preparation of the compound.

New synthesis method of N-substituted-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester

The invention discloses a new synthesis method of N-substituted-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester. The new synthesis method of the N-substituted-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester comprises the following three reaction steps: firstly, performing reaction on 4-bromopyridine hydrochloride and clR1 to prepare 4-bromine-N-substituted-pyridine chloride; then preparing N-substituted-piperidine-4-alkenyl bromide through NaBH4 reduction; finally, preparing the target product N-substituted-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester through a Grignard method and methoxy boric acid ester. The synthesis route has the advantages of high universality, cheap and easily available raw materials, mild reaction condition, few byproducts, high yield andthe like, and the product has high economic property and strong market competitiveness and is suitable for industrialized production. The formula is as shown in the description, wherein R1=-Boc;-Cbz;-Bz;-Bn;-Fmoc;-Me;-Et;-iPr;-Ph.

Novel synthesis method of N-Boc-1,2,5,6-tetrahydropyridine-4-boric acid pinacol ester

The invention discloses a novel synthesis method of N-Boc-1,2,5,6-tetrahydropyridine-4-boric acid pinacol ester. The synthesis method comprises following three steps: taking 4-bromopyridine hydrochloride as the primary raw material, reacting 4-bromopyridine hydrochloride with tert-butyl chloroformate or di-tert-butyl bicarbonate to prepare 4-bromo-N-Boc-pyridine chloride; reducing 4-bromo-N-Boc-pyridine chloride by NaBH4 to prepare N-Boc piperidine-4-vinyl bromide; and finally, carrying out coupling reactions between N-Boc piperidine-4-vinyl bromide and bis(pinacolato) diboron to prepare the target product: N-Boc-1,2,5,6-tetrahydropyridine-4-boric acid pinacol ester. The synthesis route has the advantages of easily available raw materials, mild conditions, few byproducts, and high yield, and is suitable for industrial enlarged production.

Technological method for synthesizing N-substituted-1,2,5,6-tetrahydropyridine-4-boric acid ester

The invention relates to an organic compound synthesis method, in particular to a technological method for synthesizing N-substituted-1,2,5,6-tetrahydropyridine-4-boric acid ester. The method comprises the step that N-substituted-1,2,5,6-tetrahydropyridine-4-halide serves as a raw material to react with bi-boric acid ester, cuprous halide or cuprous oxide, a ligand and organic base in a solvent, so that N-substituted-1,2,5,6-tetrahydropyridine-4-boric acid ester is obtained. The method is innovative, and easy and convenient to operate, the technological route is short, the cost is low, the product purity is high, the reaction conditions are mild, the situation that metal palladium coupling or a high-activity Grignard reagent and a low temperature condition are adopted in a traditional method is avoided, and the method has potential cost advantage, and is suitable for industrialized scale-up production.

Pyrrolopyrazole derivative and preparation method thereof, and applications of pyrrolopyrazole derivative in medicine

The present invention relates to a pyrrolopyrazole derivative and a preparation method thereof, and applications of the pyrrolopyrazole derivative in medicine, particularly to a class of new pyrrolopyrazole derivatives represented by a general formula (I), and a preparation method thereof, and uses of the pyrrolopyrazole derivatives or pharmaceutical compositions containing the pyrrolopyrazole derivatives as treating agents, particularly as gastric acid secretion inhibitors and potassium ion competitive acid blockers (P-CABs) in biomedicine, wherein various substituents (R, R and R) and the groups (X, Y and Z) in the formula (I) are defined in the specification.